ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · ESMO Open · 2026-09-16

Bayesian network meta-analysis of five first-line regimens in advanced gastric/GEJ adenocarcinoma: zolbetuximab plus chemotherapy had similar or numerically favourable OS and PFS vs immune checkpoint inhibitors at PD-L1 CPS 1–<10, but numerically worse at CPS ≥10.

Meta-analysis
Shitara et al. Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis
Oncology · ESMO Open · 2026-08-27

Post hoc analysis of RATIONALE-306 in 358 patients with advanced oesophageal squamous-cell carcinoma and PD-L1 TAP ≥5%: tislelizumab plus chemotherapy vs placebo plus chemotherapy gave median OS 19.1 vs 10.0 months (HR 0.61); grade ≥3 TRAEs 70.2% vs 66.5%.

Secondary analysisn = 358
Tougeron et al. Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆
Oncology · J Clin Oncol · 2026-04-10

Phase II trial in 114 patients with unresectable locally advanced oesophageal squamous cell carcinoma: tislelizumab with induction chemo and CRT without maintenance had better PFS than historical control (1-year 71.9% v 56.4%; HR 0.54); with maintenance it did not (HR 1.06).

RCTn = 114
Chen et al. Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)
Oncology · J Thorac Oncol · 2026-03-06

Longer follow-up of a phase 3 trial in 457 adults with extensive-stage SCLC: first-line tislelizumab plus chemotherapy kept its overall survival benefit vs placebo plus chemotherapy (median 15.5 vs 13.5 months; HR 0.78), with no new safety signals.

Secondary analysisn = 457
Fan et al. First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.